BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 11823494)

  • 1. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
    Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
    J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
    Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
    J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
    Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
    Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major.
    Stacey KJ; Blackwell JM
    Infect Immun; 1999 Aug; 67(8):3719-26. PubMed ID: 10417129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Leishmanization Using
    Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
    Front Immunol; 2020; 11():1725. PubMed ID: 33193290
    [No Abstract]   [Full Text] [Related]  

  • 6. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
    Mendez S; Tabbara K; Belkaid Y; Bertholet S; Verthelyi D; Klinman D; Seder RA; Sacks DL
    Infect Immun; 2003 Sep; 71(9):5121-9. PubMed ID: 12933855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
    Tafaghodi M; Eskandari M; Khamesipour A; Jaafari MR
    Exp Parasitol; 2011 Oct; 129(2):107-14. PubMed ID: 21767536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
    Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
    J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of interleukin-6 and interleukin-12 in bovine B lymphocytes, monocytes, and macrophages by a CpG oligodeoxynucleotide (ODN 2059) containing the GTCGTT motif.
    Zhang Y; Shoda LK; Brayton KA; Estes DM; Palmer GH; Brown WC
    J Interferon Cytokine Res; 2001 Oct; 21(10):871-81. PubMed ID: 11711000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
    Ramírez L; Santos DM; Souza AP; Coelho EA; Barral A; Alonso C; Escutia MR; Bonay P; de Oliveira CI; Soto M
    Vaccine; 2013 Feb; 31(9):1312-9. PubMed ID: 23313653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.
    Dalpke AH; Zimmermann S; Albrecht I; Heeg K
    Immunology; 2002 May; 106(1):102-12. PubMed ID: 11972638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
    Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
    J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice.
    Badiee A; Jaafari MR; Samiei A; Soroush D; Khamesipour A
    Clin Vaccine Immunol; 2008 Apr; 15(4):668-74. PubMed ID: 18235040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.
    Hartmann G; Weeratna RD; Ballas ZK; Payette P; Blackwell S; Suparto I; Rasmussen WL; Waldschmidt M; Sajuthi D; Purcell RH; Davis HL; Krieg AM
    J Immunol; 2000 Feb; 164(3):1617-24. PubMed ID: 10640783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients.
    Rafati S; Gholami E; Hassani N; Ghaemimanesh F; Taslimi Y; Taheri T; Soong L
    Vaccine; 2007 May; 25(21):4159-69. PubMed ID: 17395340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with heat-killed leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against leishmania major infection.
    Rhee EG; Mendez S; Shah JA; Wu CY; Kirman JR; Turon TN; Davey DF; Davis H; Klinman DM; Coler RN; Sacks DL; Seder RA
    J Exp Med; 2002 Jun; 195(12):1565-73. PubMed ID: 12070284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi.
    Corral RS; Petray PB
    Vaccine; 2000 Sep; 19(2-3):234-42. PubMed ID: 10930678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory DNA as adjuvant: efficacy of phosphodiester CpG oligonucleotides is enhanced by 3' sequence modifications.
    Zimmermann S; Heeg K; Dalpke A
    Vaccine; 2003 Feb; 21(9-10):990-5. PubMed ID: 12547613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
    Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
    FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.